CM InternationalWAR:CMI +1.32%73 EBITDA Margin % is 1.27% as of Mar. 2026, which is 87% below its 10-year median of 9.41. GuruFocus rates WAR:CMI with a GF Score™ of 73/100 and a GF Value™ of zł10.16 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 816 Medical Devices & Instruments companies, CM International ranks worse than 56.5% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. CM International's EBITDA for the
three
months ended in Mar. 2026 was zł0.05 Mil. CM International's Revenue for the
three
months ended in Mar. 2026 was zł3.54 Mil. Therefore, CM International's EBITDA margin for the quarter that ended in Mar. 2026 was 1.27%.
CM International (WAR:CMI) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
CM International EBITDA Margin % Related Terms
CM International EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for CM International's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:CMI vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, CM International's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CM International EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CM International's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where CM International's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CM International (WAR:CMI) has a EBITDA Margin % of 1.27% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CM International and its competitors. This is 87% below median its historical median of 9.41. Over the past decade, CM International's EBITDA Margin % has ranged from 3.33 to 16.66. According to the industry distribution chart, CM International ranks #461 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 56.5%.
Is CM International's EBITDA Margin % too high?
CM International's current EBITDA Margin % of 1.27% is 87% below median its 10-year median of 9.41. Over the past 10 years, this metric has ranged from a low of 3.33 to a high of 16.66. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. CM International's value of 1.27% is 83% below this industry median. Based on the distribution chart, CM International ranks #461 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, CM International has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CM International's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CM International ranks #461 out of 816 companies for EBITDA Margin %. This places CM International in the lower half of its industry. The industry median EBITDA Margin % is 7.48. CM International's value of 1.27% is 83% below this benchmark. Historically, CM International's own EBITDA Margin % has ranged from 3.33 to 16.66 over the past decade. While the company's 10-year median is 9.41 vs. the industry median of 7.48, CM International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CM International's current EBITDA Margin % of 1.27% is 83% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CM International and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CM International's current EBITDA Margin % is 1.27%, which is 87% below median its own 10-year median of 9.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CM International stock overvalued right now?
Based on GuruFocus' analysis, CM International (WAR:CMI) is currently considered Modestly Undervalued. The stock's GF Value™ is zł10.16, compared to a current price of zł7.70 — trading 24.2% below its estimated fair value. The current EBITDA Margin % is 1.27%, which is 87% below median its 10-year median of 9.41 and 83% below the Medical Devices & Instruments industry median of 7.48. CM International's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For CM International (WAR:CMI), the current EBITDA Margin % is 1.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CM International (WAR:CMI) Overvalued in 2026?
Based on GuruFocus' analysis, CM International stock appears to be undervalued.
The current stock price of zł7.70 is trading 24.2% below its estimated GF Value™ of zł10.16.
GuruFocus considers CM International to be Modestly Undervalued.
Key valuation signals for WAR:CMI:
EBITDA Margin %: 1.27% (87% below median its 10-year median of 9.41)
GF Value™: zł10.16 vs. price of zł7.70 (24.2% below fair value)
Industry Position: 83% below the Medical Devices & Instruments median (#461 of 816)
No single metric tells the full story. See the WAR:CMI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CM International SA is a Poland based medical device company. It offers devices which include Big bfc which is a Multifunctional device for skin, face and body;PresoLimf which is a Lymphatic drainage machine and other devices like M3, Smalll bfc and Nuximia.
73GF Score
Get the complete analysis for WAR:CMI
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:CMI has been successfully added to your 
